UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 91

Sortiert nach

NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls

Modern pathology, 2020-01, Vol.33 (1), p.38-46

2020

Volltextzugriff (PDF)

A Performance Comparison of Commonly Used Assays to Detect RET Fusions

Clinical cancer research, 2021-03, Vol.27 (5), p.1316-1328

2021

Volltextzugriff (PDF)

TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations

Clinical cancer research, 2020-04, Vol.26 (7), p.1624-1632

2020

Volltextzugriff (PDF)

EZH2 inhibition: it’s all about the context

JNCI : Journal of the National Cancer Institute, 2023-11, Vol.115 (11), p.1246-1248

2023

Volltextzugriff (PDF)

Tumour lineage shapes BRCA-mediated phenotypes

Nature (London), 2019-07, Vol.571 (7766), p.576-579

2019

Volltextzugriff (PDF)

Functional Genomic Analyses Identify Pathways Dysregulated by Progranulin Deficiency, Implicating Wnt Signaling

Neuron (Cambridge, Mass.), 2011-09, Vol.71 (6), p.1030-1042

2011

Volltextzugriff (PDF)

Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies

Nature communications, 2022-11, Vol.13 (1), p.7182-7182, Article 7182

2022

Volltextzugriff (PDF)

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers

Nature communications, 2022-03, Vol.13 (1), p.1450-1450, Article 1450

2022

Volltextzugriff (PDF)

Pathologic complete response to KEYNOTE522 and HER2-directed therapy for synchronous TNBC and HER2+ breast cancer

NPJ precision oncology, 2024-07, Vol.8 (1), p.162-6, Article 162

2024

Volltextzugriff (PDF)

Evaluation of a Shape-Based Model of Human Face Discrimination Using fMRI and Behavioral Techniques

Neuron (Cambridge, Mass.), 2006-04, Vol.50 (1), p.159-172

2006

Volltextzugriff (PDF)

Author Correction: The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers

Nature communications, 2022-04, Vol.13 (1), p.1936-1936, Article 1936

2022

Volltextzugriff (PDF)

Author Correction: Tumour lineage shapes BRCA-mediated phenotypes

Nature (London), 2020-01, Vol.577 (7789), p.E1-E1

2020

Volltextzugriff (PDF)

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

The New England journal of medicine, 2020-08, Vol.383 (9), p.813-824

2020

Volltextzugriff (PDF)

Abstract PS11-06: Efficacy and safety of larotrectinib in patients with TRK fusion breast cancer

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS11-06-PS11-06

2021

Volltextzugriff (PDF)

Phase 1/2 dose expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with ER+ metastatic breast cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.1080-1080

2023

Volltextzugriff (PDF)

First-in-human phase 1/2 dose escalation and expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with solid tumors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.3081-3081

2022

Volltextzugriff (PDF)

Abstract OT2-23-01: A Phase 1b/2a, open-label platform study to evaluate mirdametinib in combination with fulvestrant in ER+ metastatic breast cancers harboring MAPK-activating mutations

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.OT2-23-01-OT2-23-01

2022

Volltextzugriff (PDF)

A phase 1/2 study of CFT1946, a novel, bifunctional degradation activating compound (BIDAC) degrader, of mutant BRAF V600 as monotherapy and in combination with trametinib, in mutant BRAF V600 solid tumors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS3163-TPS3163

2023

Volltextzugriff (PDF)

MYC amplification segment-size mutual exclusivity analysis with other oncogenic events in a pan-cancer sequencing cohort

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3073-3073

2023

Volltextzugriff (PDF)

Tumor-agnostic genomic and clinical analysis of solid tumors with BRAF fusions

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3146-3146

2023

Volltextzugriff (PDF)

Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib

Clinical cancer research, 2024-02, Vol.30 (4), p.687

2024

Volltextzugriff (PDF)

Abstract CC04-01: First-in-human biomarker-driven phase I TRESR trial of ataxia telangiectasia and Rad3-related inhibitor (ATRi) RP-3500 in patients (pts) with advanced solid tumors harboring synthetic lethal (SL) genomic alterations

Molecular cancer therapeutics, 2021-12, Vol.20 (12_Supplement), p.CC04-01-CC04-01

2021

Volltextzugriff (PDF)

BRCA reversion mutations in a pan-cancer cohort to reveal BRCA- dependence in select noncanonical BRCA- mutant histologies

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3012-3012

2021

Volltextzugriff (PDF)

Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results

Nature medicine, 2023-06, Vol.29 (6), p.1400-1411

2023

Volltextzugriff (PDF)

1 – 25 von 91

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(87)
Mit Volltextzugriff
(77)

Publikationsform

Artikel
(90)
Dissertationen
(1)

Sprache

Englisch
(91)
Japanisch
(14)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls

A Performance Comparison of Commonly Used Assays to Detect RET Fusions

TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations

EZH2 inhibition: it’s all about the context

Tumour lineage shapes BRCA-mediated phenotypes

Functional Genomic Analyses Identify Pathways Dysregulated by Progranulin Deficiency, Implicating Wnt Signaling

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib

Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers

Pathologic complete response to KEYNOTE522 and HER2-directed therapy for synchronous TNBC and HER2+ breast cancer

Evaluation of a Shape-Based Model of Human Face Discrimination Using fMRI and Behavioral Techniques

Author Correction: The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers

Author Correction: Tumour lineage shapes BRCA-mediated phenotypes

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

Abstract PS11-06: Efficacy and safety of larotrectinib in patients with TRK fusion breast cancer

Phase 1/2 dose expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with ER+ metastatic breast cancer

First-in-human phase 1/2 dose escalation and expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with solid tumors

Abstract OT2-23-01: A Phase 1b/2a, open-label platform study to evaluate mirdametinib in combination with fulvestrant in ER+ metastatic breast cancers harboring MAPK-activating mutations

A phase 1/2 study of CFT1946, a novel, bifunctional degradation activating compound (BIDAC) degrader, of mutant BRAF V600 as monotherapy and in combination with trametinib, in mutant BRAF V600 solid tumors

MYC amplification segment-size mutual exclusivity analysis with other oncogenic events in a pan-cancer sequencing cohort

Tumor-agnostic genomic and clinical analysis of solid tumors with BRAF fusions

Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib

Abstract CC04-01: First-in-human biomarker-driven phase I TRESR trial of ataxia telangiectasia and Rad3-related inhibitor (ATRi) RP-3500 in patients (pts) with advanced solid tumors harboring synthetic lethal (SL) genomic alterations

BRCA reversion mutations in a pan-cancer cohort to reveal BRCA- dependence in select noncanonical BRCA- mutant histologies

Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results

Suchergebnisse filtern